RAS-pathway mutations are common in patients with ruxolitinib refractory/intolerant myelofibrosis: molecular analysis of the PAC203 cohort

Detalles Bibliográficos
Autores principales: O’Sullivan, J. M., Taylor, J., Gerds, A., Buckley, S., Harrison, C. N., Oh, S., List, A. F., Howard, K., Dreau, H., Hamblin, A., Mead, A. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10681886/
https://www.ncbi.nlm.nih.gov/pubmed/37864122
http://dx.doi.org/10.1038/s41375-023-02027-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10681886/
https://www.ncbi.nlm.nih.gov/pubmed/37864122
http://dx.doi.org/10.1038/s41375-023-02027-3

Ejemplares similares